We have infused recombinant factor Vlla into patients with hereditary factor VI1 deficiency with marked reductions in plasma concentrations of factor IX activation peptide (FIXP), factor X activation peptide (FXP), and prothrombin activation tragment F,,,. These investigations show substantial elevations in these markers of coagulation activation and thereby demonstrate that the factor VII-tissue factor pathway is largely responsible for the activation of factor IX as well as factor X in the basal state (ie, the absence of thrombosis or provocative stimuli). We have administered a monoclonal antibody purified factor IX concentrate to individuals with hemophilia 6. These studies show an increase in the plasma levels of FIXP that were initially greatly decreased, but no H E BLOOD COAGULATION mechanism is classi-T cally described as functionally independent intrinsic and extrinsic pathways that separately activate factor X and generate thrombin.'.' It is thought that endothelial cell damage exposes subendothelial components, which allows blood to contact collagen and tissue factor, thereby individually triggering activation of the two pathways. However, both intrinsic and extrinsic pathways are required for normal hemostasis because isolated coagulation protein deficiencies in either pathway lead to bleeding disorders. These observations prompted investigators to search for direct interactions between the intrinsic and extrinsic pathways as well as indirect interactions via the common pathway. In the 1960s, circumstantial evidence was produced, using crude in vitro systems, showing that extrinsic pathway components could produce factor 1Xa in plasma.3~~ However, it was not until 1977 that tissue factor and factor VIIa were shown to activate purified factor IX.' Subsequently, factor IXa and factor Xa were demonstrated to convert factor VI1 to factor VIIa.6,7 Finally, thrombin and factor Xa were shown to activate factor VIII, which substantially augments the rate of factor IXa action on factor x.*-" Despite these major advances, we know remarkably little about in vivo coagulation mechanism function in the basal state (ie, the absence of thrombosis or provocative stimuli). Dogs with a severe isolated factor VI11 deficiency constitute an interesting animal model in which to examine the linkage between the intrinsic and extrinsic pathways. Giles et all' have provided indirect evidence, using the cuticle bleeding time, that the factor VII-tissue factor mechanism can mediate factor Xa generated via factor IXa. The immunoassays for activation peptides of human factor IX," human factor X,14 and human prothrombin'',16 have provided tools for directly assessing in vivo function of the blood coagulation mechanism. This methodology has shown that patients with factor VI1 deficiency, but not factor XI deficiency, have reduced levels of factor IX activation, whereas patients with deficiencies of factor VIII or factor IX have normal levels of factor X and prothrombin activation under basal conditions. These observations have prompted us to suggest that the extrinsic pathway activates change in FXP or F,,,. We have also infused highly purified factor Vlll concentrate into patients with hemophilia A. The data demonstrate no significant changes in the plasma concentrations of FXP and F,,,. The above observations indicate that factor IXa generated by the factor VII-tissue factor pathway is unable to activate factor X under basal conditions. Based upon the above findings, we outline a model of blood coagulation system function under basal conditions, and suggest a process by which the generation of factor Xa and thrombin might be accelerated during normal hemostasis and in the setting of thrombotic disorders. 0 1992 by The American Society of Hematology.
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the intrinsic pathway, but that the intrinsic pathway is dormant with regard to the generation of factor Xa or thr~mbin.'~.'~ In this report, we directly characterize in vivo interactions between the extrinsic and intrinsic pathways, show a critical in vivo kinetic block in the intrinsic pathway, and propose a model by which the intrinsic pathway may contribute to factor Xa and thrombin generation during normal hemostasis, and in the setting of thrombotic disorders.
MATERIALS AND METHODS
Venipunctures were performed atraumatically with 19-or 21-gauge butterfly infusion sets using a two-syringe technique. Blood samples were drawn into plastic syringes preloaded with the appropriate solutions as described below. (1) For all functional and immunologic assays of clotting factors, 3.8% (wt/vol) sodium citrate was employed; the ratio of anticoagulant to blood used was 0.1:0.9 (vol/vol). (2) For assays of factor IX activation peptide (FIXP), factor X activation peptide (FXP), and F,,,, an anticoagulant containing ACD (38 Collection andprocessing of blood samples. mmol/L citric acid, 75 mmol/L sodium citrate, 136 mmol/L dextrose), 6 mmol/L EDTA, 6 mmol/L adenosine, and 25 U/mL heparin was used; the ratio of anticoagulant to blood used was 0.29.0 (vol/vol). (3) For the fibrinopeptide A (FPA) assay, an anticoagulant containing a thrombin inhibitor, EDTA, and aprotinin was purchased from Byk-Sangtec (Dietzenbach, Germany); the ratio of anticoagulant to blood used was O.LO.9 (vol/vol). After collection of blood samples, plasma fractions were obtained by centrifugation at 4°C for 15 minutes at 1,600g and stored at -80°C before use.
Routine coagulation tests were performed using standard laboratory methods. Measurements of fibrinogen (fibrin) degradation products were determined using the ThromboWellcotest (Wellcome Reagents, Research Triangle Park, NC).
The coagulant activities of prothrombin, factor VII, factor IX, and factor X were measured by standard one-stage assays using congenitally deficient plasmas. The concentrations of factor VII/ VIIa antigen were determined by a solid-phase double-antibody enzyme-linked immunosorbent assay using a kit provided by Novo Nordisk (Gentofte, Denmark)." A normal plasma pool was constructed by mixing equal volumes of plasma from more than 30 control subjects. This population consisted of healthy laboratory and medical personnel between the ages of 20 and 50 years, who gave a negative history for bleeding as well as thrombosis, and were not taking any medications at the time of sample collection. The plasma concentrations of FIXP, FXP, and F,,, were determined by double-antibody radioimmunoassay as described in earlier reports from our lab~ratory.'~-'~ The FPA measurements were established by radioimmunoassay with a kit provided by Byk-Sangtec (Dietzenbach, Germany).
A Estimation of relative immunoreactivity, computation of the slopes of the dose-response curves, as well as determinations of the various associated indices were obtained by a least-squares fit of the radioimmunoassay results to a "fourparameter" model as described by Rodbard et a1.18.19 Statistical analyses of data were conducted by standard techniquesm In most instances, the means are provided with associated standard deviations.
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RESULTS
We have previously demonstrated that plasma concentrations of FIXP, FXP, and F,,, are significantly decreased in patients with hereditary factor VI1 defi~iency.'~.'~ However, individuals with factor XI deficiency have normal levels of FIXP," FXP, and F,,, (unpublished data). These data suggest that factor VII-tissue factor pathway activity mainly determines the extent of factor IX and factor X activation under basal conditions. To show that this is the case, we infused rFVIIa into patients with hereditary factor VI1 deficiency. Two homozygous factor VII-deficient individuals with reduced levels of FIXP, FXP, and F,,, were hospitalized at the General Clinical Research Center of the Beth Israel Hospital (Boston, MA). Both individuals were asymptomatic and had not received factor VII-containing products for at least 5 days before investigation. After obtaining baseline blood studies, rFVIIa was administered to each patient via a peripheral vein as a bolus at a dosage of 10 pglkg of body weight. Blood samples were obtained by separate venipunctures at various time points from 15 minutes to 24 hours after administration of the procoagulant. Several weeks later, both patients received a second infusion of rFVIIa at a dosage of 20 pglkg of body weight as outlined above. During these investigations, no changes were observed in platelet count, plasma fibrinogen concentration, or fibrinogen (fibrin) degradation products.
The first patient was a 17-year-old male with a lifelong history of severe bleeding similar to that of patients with hemophilia A or B. Before infusion, the measurements of plasma factor VI1 antigen and coagulant activity were less than 1% of normal (Table 1) . After administration of rFVIIa, immediate elevations were observed in the plasma concentrations of factor VII/VIIa antigen and coagulant activity ( Table 1) . Measurements of FIXP and FXP increased at the earliest postinfusion time point, whereas a gradual elevation was noted in the plasma levels of F,,, (Fig  1) . This latter parameter reached a maximum value at 1 hour with infusion of 10 pg/kg of rFVIIa, and at 30 minutes with administration of 20 pg/kg of rFVIIa. The second patient was a 21-year-old woman with a history of menorrhagia that was effectively controlled with oral contraceptives. This medication was discontinued several months before administration of rFVIIa. Before infusion, the measurements of plasma factor VI1 antigen and coagulant activity were 16% and 3% of normal levels, respectively (Fig 2) . After administration of rFVIIa, an immediate increase in the plasma concentration of factor VII/VIIa antigen was observed at the earliest time point, whereas a gradual elevation was noted in the plasma levels of FIXP, FXP, and F,,,. The maximum plasma concentration of FXP was attained at 30 minutes whereas maximum plasma levels of FIXP and F,,, were reached at 2 hours, which was substantially later than the peak plasma concentrations of factor VII/VIIa antigen (Fig 2) . In both patients, the concentrations of the various activation peptides gradually decreased to baseline levels as rFVIIa was cleared from the circulation. While both individuals manifested greater elevations in the plasma concentrations of the activation peptides with infusion of higher amounts of rFVIIa, the qualitative responses were similar in each of the patients at the two doses of procoagulant. It is also of interest to note that the first patient exhibited increased plasma concentrations of FPA to greater than 3 nmol/L at 30 minutes after administration of both doses of rFVIIa, whereas the second patient experienced no such increments in thrombin-dependent cleavage of fibrinogen (data not shown).
We next investigated the effect of factor IX replacement on plasma concentrations of FIXP, FXP, and F,,, in hemophilia B patients. These studies provide us with a unique opportunity to detect in vivo factor IXa-dependent activation of factor X under nearly basal conditions. Eleven males (median age, 34 years; range, 16 to 61 years) were treated for mild bleeding episodes (eg, simple hemarthroses, hematomas, epistaxis, and hematuria) with infusion of MoAb-purified factor IX concentrate at a dosage of 100 U/kg of body weight. These studies were performed at the A. Bianchi Bonomi Hemophilia and Thrombosis Center (Milan, Italy). All patients exhibited baseline plasma concentrations of factor IX activity that were less than 1% of normal levels, and had not been treated with factor IXcontaining products during the preceding week. Blood samples were obtained before administration of the purified procoagulant, and after infusion of the concentrate at five different time points from 15 minutes to 360 minutes. The plasma concentrations of prothrombin activity, factor VI1 activity, factor IX activity, and factor X activity were determined over the above time interval (Table 2 ). The plasma levels of FIXP (Table 3) , FXP (Table 4) , and F,,, (Table 5) were also ascertained over the same time period. Two individuals (nos. 6 and 7) exhibited near normal concentrations of factor IX antigen before infusion of For concentrate (CRM'), whereas one individual (no. 8) possessed a level of zymogen that was 14% of normal values (CRMR). It is of interest that one CRM' patient (no. 7) possessed a baseline plasma FIXP value (80.4 pmol/L) that was considerably greater than any other individual with hemophilia B. This situation may reflect the presence of a factor IX mutation in which the zymogen can be activated in a near normal fashion, but the abnormal factor IXa does not possess enzymatic activity.*' We note that the mean plasma concentration of factor IX activity in the 11 patients was maximal at 15 minutes, and then declined to a mean plasma value of 77% of normal at the 6-hour time point. No significant changes were observed in the mean plasma levels of prothrombin activity, factor VI1 activity, or factor X activity. We also observed that the very low baseline plasma FIXP concentrations gradually increased by nearly tenfold over a 4-hour period (Table 3) , but were not accompanied by significant increments in the mean plasma levels of FXP (Table 4) , F,,, (Table 5) , or FPA (data not shown). However, occasional patients exhibited modest elevations (20% to 50%) of plasma concentrations of FXP (Table 4 ; nos. 3 through 7), while others showed slight augmentations (20% to 40%) of plasma levels of F,,, (Table 5 ; nos. 1 and 10). We then examined the effects of factor VIII replacement on the plasma concentrations of FIXP, FXP, and F,,, in hemophilia A patients. These studies allowed us to monitor the potential in vivo action of factor VIII on the factor IXa-dependent activation of factor X under nearly basal conditions. Two males with severe hemophilia A were infused with rFVIII at a dose of 50 U/kg of body weight. These studies were performed at the New England Hemophilia Center (Worcester, MA). Neither individual had sustained a recent bleeding episode or received the above procoagulant over the previous 7 days. Blood samples were obtained before administration of rFVIII, and after infusion of the concentrate at three different time points, from 1 hour to 12 hours. The plasma concentrations of factor VI11 activity, FXP, and F,,, were determined over the above time interval (Fig 3) . The plasma levels of factor VI11 activity were elevated from less than 1% of normal values before the infusion to greater than 100% during the first 3 hours after administration of the procoagulant. We noted that the plasma concentrations of FXP and F,,,, as well as FPA (data not shown), were unchanged after normalization of plasma levels of factor FVIII. Within 2 weeks of the rFVIII infusions, the same patients were restudied while receiving an identical dose of MoAb-purified factor VI11 concentrate derived from pooled plasma. The results obtained were similar to those observed with the rFVIII (data not shown).
To ascertain whether basal activity of the factor VIItissue factor pathway might substitute for intrinsic pathway function, we correlated the plasma concentrations of FIXP, FXP, F,,,, and FPA with the severity of bleeding in 35 Italian patients (median age, 37 years; range, 7 to 64 years) with hemophilia A. All individuals exhibited plasma levels of factor VI11 coagulant activity less than 1% of normal, and none had received factor VIII-containing products for at least 7 days before investigation. The plasma levels of FIXP, FXP, and F,,, constitute stable parameters of a particular hemophiliac at a given point in time. This conclusion was reached by demonstrating that two blood samples obtained over a 2-month period were virtually identical (data not shown). Eighteen patients exhibited a severe bleeding disorder typical of most hemophiliacs with this degree of factor VI11 deficiency. These patients, termed "severe-severe hemophiliacs," have crippling arthropathy, averaged 30 or more treated spontaneous hemorrhages per year over the preceding 5-year period, and consume more than 50,000 U/yr of factor VI11 concentrate. Seventeen age-matched patients with plasma levels of factor VI11 identical to the "severe-severe'' group exhibit a relatively milder bleeding disorder. These individuals, termed "mildsevere hemophiliacs," have no significant arthropathy, averaged fewer than three treated spontaneous hemorrhages per year over the past 5 years, and consume less than 5,000 U/yr of factor VI11 concentrate. The "severe-severe'' and "mild-severe" hemophiliacs possess indistinguishable plasma levels of FIXP, FXP, and F,+2, respectively (Fig 4), which indicates that the variable expression of this disorder is not secondary to the basal activity of the factor VII-tissue factor pathway.
DISCUSSION
We have used immunoassays for activation peptides of coagulation proteins to monitor the transitions of zymogens to serine proteases (eg, FIXP, FXP, and F1+2)13-16 as well as to evaluate the conversion of fibrinogen to fibrin (eg, FPA).".23 This methodology shows that the blood coagulation mechanism is normally active in humans, albeit at extremely low levels.% We recently reported that factor VII-deficient patients exhibit marked reductions in the plasma concentrations of FIXP, while factor XI-deficient individuals possess plasma levels of FIXP that are indistinguishable from those of a normal age-matched control population." We also observed that factor VII-deficient patients exhibit plasma concentrations of FXP and Fl+, that are significantly decreased as compared with individuals with either factor VI11 or factor IX deficiencies, or a normal age-matched control pop~lation.'~ These data suggest that the basal activity of the hemostatic mechanism (ie, coagulation system activity in the absence of thrombosis or provocative stimuli) is mainly attributable to factor VII-tissue factor pathway function, which is responsible for the continuous generation of factor IXa, factor Xa, and thrombin. Furthermore, it would appear that generated factor 
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IXa is unable to convert factor X to factor Xa because deficiencies of factor IX or factor VI11 have no effect on the plasma levels of FXP and F,+,.
The validity of this novel model of the blood coagulation mechanism was tested by administering relatively small doses of rFVIIa (10 to 20 p.g/kg of body weight) to patients with severe factor VI1 deficiency that resulted in the in vivo generation of increased plasma concentrations of factor IXa, factor Xa, and thrombin, as measured by activation peptide assays. It is of interest to note that the extrinsic pathway generation of factor IXa is approximately equivalent to that of factor Xa when corrected for the somewhat different rates of clearance of the two peptides. This should resolve lingering doubts about the physiologic significance of the factor VII-tissue factor pathway in factor IX activation. The amounts of rFVIIa infused are approximately one-fifth of that reported to exert a prohemostatic effect in patients with factor VI11 inhibitor^.^^-^' The above studies cannot determine the extent to which the plasma concentrations of factor Xa and thrombin generated in the factor VII-deficient patients are caused by feedback activation of the intrinsic cascade. However, we suspect that the factor Xa and thrombin produced by the factor VII-tissue factor pathway in this setting are insufficient and/or not properly localized to mobilize intrinsic cascade function (see below).
The activation of factor IX and factor X by rFVIIa undoubtedly arises from the interaction of infused enzyme with endogenous tissue factor in vivo. Indeed, we have recently observed that an antibody to tissue factor completely suppresses the activation of factor IX, factor X, and prothrombin mediated by rFVIIa in normal chimpanzees (unpublished data). In response to rFVIIa, we observed that the two factor VII-deficient patients exhibited a qualitatively different temporal response in factor IX and factor X activation. The patient with virtually no factor VI1 antigen demonstrated an immediate increase in the plasma concentrations of FIXP and FXP, while the individual with baseline factor VI1 antigen and factor VI1 coagulant activity levels of 16% and 3% of normal, respectively, displayed a gradual increase in these activation peptides. We speculate that this difference is attributable to the occupancy of tissue factor sites by dysfunctional endogenous factor VI1 molecules that act as a competitive inhibitor of the infused procoagulant.
We then examined our hypothesis that the factor IXafactor VIII/VIIIa cell surface complex is unable to contribute to the basal activation of factor X and prothrombin by infusing highly purified concentrates of factor IX and factor VI11 into patients with hemophilia B and hemophilia A, respectively. The amounts of concentrate administered were sufficient to raise plasma concentrations of either factor IX or factor VIII to greater than 100% of normal values. The factor IX-deficient patients exhibited very low mean baseline plasma concentrations of FIXP that increased dramatically after infusion of purified factor IX concentrate. However, the mean plasma levels of FXP, F,,,, and FPA were not significantly altered. It is of interest to note that the mean plasma concentrations of FIXP increased gradually into the normal range over several hours despite the presence of maximal intravascular factor IX levels within 15 minutes postinfusion. This is to be contrasted with the relatively rapid increase in plasma concentrations of FIXP observed when factor VIIa was infused into the patient with little or no factor VI1 antigen. We have no explanation for this discrepancy except to suggest that a time-dependent cleavage of factor VI1 by factor IXa might be required to accelerate extrinsic pathway function. The two factor VIII-deficient patients exhibited normal plasma concentrations of FXP, F,,,, and FPA that were unchanged after administration of either rFVIII or MoAb-purified plasma factor VI11 concentrate. Thus, the factor IXa-factor VIIIa-cell surface complex plays no demonstrable role in factor Xa-mediated thrombin generation in the basal state.
The kinetic block in the in vivo action of factor IXa on factor X may be caused by the absence of circulating factor VIIIa, or the lack of an appropriate natural surface for assembly of factor IXa-factor VIIIa-factor X complex, or the action of a particularly potent natural anticoagulant mechanism.% The currently available in vitro data would suggest that thrombin-or factor Xa-mediated production of factor VIIIa and/or generation of a platelet surface for assembly of the factor IXa-factor VIIIa-factor X complex probably represents the critical step in the activation of the intrinsic ca~cade.8.~~-" Indeed, recent in vitro studies indicate that thrombin may also be involved in factor XI activation, which could then augment existing plasma levels of factor IXa?Z.33 Based on the above in vitro observations, we suspect that vascular injury or thrombotic stimuli leads to increased formation of free thrombin, or factor Xa, via the action of the factor VII-tissue factor pathway, which then generates factor VIIIa and/or creates a natural surface (eg, activated platelets) on which the assembly of factor VIIIa-factor IXa complex takes place. The increased levels of free thrombin might also serve as a booster pump to somewhat augment the plasma concentrations of factor IXa. This chain of events would result in augmented factor Xa production and, ultimately, thrombin generation from the action of factor IXa on factor X. The above hypothesis is consistent with the severe bleeding tendency of most patients with factor VI11 or factor IX deficiency, and the insensitivity of the FXP and F,,, assays to significant deficiencies of these two proteins.
The precise anatomic site where the factor VIIa-tissue factor complex activates factor IX and factor X has not been defined. This interaction could occur on the surface of endothelial cells, but tissue factor has not been observed in this locale.M However, the experimental methods used may not have been sufficiently sensitive to detect the extremely small quantities of tissue factor required to initiate extrinsic pathway function. It is also possible that this event takes place outside blood vessels because of the normal passage of coagulation proteins through endothelial cellsg5 into subendothelial tissues that constitutively express tissue f a~t o r .~~'~~ It is presently unknown whether factor VIII, a molecule that circulates in association with huge von Willebrand's multimers, could gain access to this postulated extravascular compartment. Thus, it could be argued that the observed block in factor IXa action on factor X might For personal use only. on November 11, 2017. by guest www.bloodjournal.org From be caused by spatial localization of the components of the factor IXa-factor VIIIa-factor X complex. This explanation is probably not correct because direct infusion of factor XIa into the vascular system of chimpanzees also indicates the presence of a block in the factor IXa-dependent cleavage of factor X (unpublished data).
We have previously shown that certain individuals with prethrombotic disorders show elevations in prothrombin to thrombin conversion rates of approximately twofold to fourfold, as measured systemically by the F,,, assay without substantial fibrin formation as quantified by the FPA a~say,9'*~* whereas patients sustaining acute thrombotic events exhibit F,,, levels that are elevated by about 10-fold.I6,j9 The conversion of a prethrombotic state to a thrombotic event probably results from small increases in the generation rates of hemostatic enzymes that exceed the inhibitory threshold of an individual's endogenous anticoagulant mechanisms, as well as the sequestration of these proteases on specialized cell surfaces. The critical unanswered question is whether persons who are prethrombotic, from a biochemical standpoint, are more likely to respond in a hypersensitive fashion to environmental stimuli, and thereby generate small increments in the amounts of extrinsic pathway-generated free thrombin, because their blood coagulation mechanisms are closer to the threshold of normal inhibitory processes. The thrombin that is generated could then be used to ignite the dormant intrinsic cascade, which could ultimately result in the generation of large amounts of free enzyme and the development of arterial or venous thrombosis.
